The science, economics, and effectiveness of combination therapy for hepatitis C
Authors:
- G DusheikoGDG Dusheiko
- E BarnesEBE Barnes
- G WebsterGWG Webster
- S WhalleySWS Whalley
Abstract
No abstract availableThis publication has 21 references indexed in Scilit:
- Occult Hepatitis B Virus Infection in Patients with Chronic Hepatitis C Liver DiseaseNew England Journal of Medicine, 1999
- An infectious molecular clone of a Japanese genotype 1b hepatitis C virusHepatology, 1999
- Rising Incidence of Hepatocellular Carcinoma in the United StatesNew England Journal of Medicine, 1999
- In pursuit of quality: the National Institute for Clinical ExcellenceThe Lancet, 1999
- Making sense of hepatitis CThe Lancet, 1999
- Combination therapy with interferon alfa and ribavirin as retreatment of interferon relapse in chronic hepatitis C.1999
- Ribavirin and interferon alfa‐2b in chronic hepatitis C: assessment of possible pharmacokinetic and pharmacodynamic interactionsBritish Journal of Clinical Pharmacology, 1998
- Interferon Alfa-2b Alone or in Combination with Ribavirin as Initial Treatment for Chronic Hepatitis CNew England Journal of Medicine, 1998
- Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis CThe Lancet, 1997
- Natural history of liver fibrosis progression in patients with chronic hepatitis CThe Lancet, 1997